Applications including "USP"

GA397 - Analysis of Nitromethane(Under the Condition of draft for USP, Tromethamine Hydrochloride, Limit of Nitromethane) -

GC InertSearch InertCap 624MS
LC110 - Analysis of Quinic acid, Malic acid, Citric acid, Shikimic acid (Under the Condition of draft for USP, Aronia melanocarpa Fruit Aqueous Dry Extract, IDENTIFICATION C.HPLC PROFILE AND RATIO OF ORGANIC ACIDS) -

LC InertSearch InertSustain AQ-C18
LC109 - Analysis of Prazosin hydrochloride (Under the Condition of draft for USP, Prazosin Hydrochloride Compounded Oral Suspension, ASSAY) -

LC InertSearch InertSustainC18
LC108 - Analysis of Formoterol fumarate (Under the Condition of draft for USP, Formoterol Fumarate Inhalation Solution, Assay) -

LC InertSearch InertCore C8
LC107 - Analysis of Terbinafine hydrochloride (Under the Condition of USP41-NF36,Terbinafine Tablets, IMPURITIES (LIMIT OF TERBINAFINE DIMER)) -

LC InertSearch Inertsil Hybrid-C18
LC100 - Analysis of Omeprazole(Under the Condition of USP41-NF36, Omeprazole Delayed-Release Capsules, ASSAY) -

LC InertSearch InertSustain C8
LL043 - Analysis of Azithromycin (Based on the Condition of USP-NF 2025 Issue 2 Mar, Azithromycin Tablets, ORGANIC IMPURITIES) -

LC InertSearch Inertsil Hybrid-C18
LC099 - Analysis of Ascorbic acid (Under the Condition of draft for USP, Water-Soluble Vitamins Chewable Gels, Ascorbic acid, Method 1) -

LC InertSearch InertSustain C8
LC098 - Analysis of Tramadol Hydrochloride (Under the Condition of draft for USP, Tramadol Hydrochloride Tablets, ASSAY) -

LC InertSearch InertSustain C8
LC097 - Analysis of Azithromycin (Based on the Condition of USP NF 2025 Issue 2 Mar, Azithromycin Tablets, ORGANIC IMPURITIES) -

LC InertSearch Inertsil Hybrid-C18
LC096 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ORGANIC IMPURITIES) -

LC InertSearch InertSustainSwift C18
LC095 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ASSAY) -

LC InertSearch InertSustainSwift C18
LC073 - Analysis of Yohimbine Hydrochloride(Under the Condition of USP41-NF36,Yohimbine Injection, ASSAY) -

LC InertSearch InertSustain C18
LC072 - Analysis of Vitamin K１ (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PHYTONADIONE) -

LC InertSearch InertSustain C18
LC071 - Analysis of Acetaminophen(Under the Condition of USP41-NF36, Acetaminophen Oral Solution, ASSAY) -

LC InertSearch Inertsil WP300 C18
LC070 - Analysis of Vitamin A (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin A,Method 1) -

LC InertSearch InertSustain NH2
LC066 - Analysis of Cidofovir (Under the Condition of USP43-NF38, Cidofovir, ASSAY) -

LC InertSearch Inertsil Hybrid-C18
LC065 - Analysis of Vitamin E (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 1) -

LC InertSearch InertSustain C18
LC062 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin, DISSOLUTION) -

LC InertSearch Inertsil Hybrid-C18
LC061 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin,ASSAY) -

LC InertSearch Inertsil Hybrid-C18
LC058 - Analysis of Folic acid (Under the Condition of USP NF 2022 ISSUE 3, <411>FOLIC ACID ASSAY,_Procedure 1) -

LC InertSearch InertSustainSwift C18
LC057 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Tablets, ASSAY) -

LC InertSearch InertSustain C18
LC056 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol, ASSAY) -

LC InertSearch InertSustain C18
LC055 - Analysis of Dobutamine (Under the Condition of the USPNF 2023 Issue 2, Dobutamine Hydrochloride, ASSAY) -

LC InertSearch Inertsil WP300 C18
LC054 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Injection, ASSAY) -

LC InertSearch InertSustain C18
LC053 - Analysis of Folic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,FOLIC ACID_Method 2) -

LC InertSearch InertSustain C8
LC052 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 2) -

LC InertSearch InertSustain C8
LC051 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 1) -

LC InertSearch InertSustain AQ-C18
LC050 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 3) -

LC InertSearch Inertsil WP300 C18
LC049 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 2) -

LC InertSearch InertSustain C18
LC044 - Analysis of Calcium Pantothenate (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Calcium Pantothenate, Method1) -

LC InertSearch InertSustainSwift C18
LC042 - Analysis of Nicotinic acid,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method3 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method3) -

LC InertSearch InertSustain C8
LC041 - Analysis of Nicotinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method1 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method1) -

LC InertSearch InertSustain C18
LC040 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, IMPURITIES, Limit of Free 4-Aminophenol) -

LC InertSearch InertSustainSwift C8
LC039 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, ASSAY) -

LC InertSearch InertSustainSwift C8
LC036 - Analysis of Zonisamide (Under the Condition of USP41-NF36, Zonisamide Compounded Oral Suspension, ASSAY) -

LC InertSearch InertSustain C18
LC035 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide Capsules, ASSAY) -

LC InertSearch InertSustain C18
LC034 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide, ASSAY) -

LC InertSearch InertSustain C18
LC033 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Oil- and Water-Soluble Vitamins Minerals Tablets,BIOTIN_Method 3) -

LC InertSearch InertSustain C18
LC032 - Analysis of D‐Biotin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,BIOTIN_Method 1) -

LC InertSearch InertSustain C8
LC031 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Biotin) -

LC InertSearch InertSustain C8
LC029 - Analysis of Riboflavin (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,RIBOFLAVIN_Method 2) -

LC InertSearch InertSustain C18
LC028 - Analysis of Pyridoxine hydrochloride (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PYRIDOXINE HYDROCHLORIDE_Method 2) -

LC InertSearch InertSustain C18
LC027 - Analysis of Nicotinamide (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,NIACINAMIDE_Method 2) -

LC InertSearch InertSustain C18
LC026 - Analysis of Nicotinic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin_Method 2) -

LC InertSearch InertSustain C18
LC025 - Analysis of Eplerenone (Under the Condition of draft for USP, Eplerenone Tablets, ASSAY) -

LC InertSearch InertSustain AQ-C18
LC024 - Analysis of Eplerenone (Under the Condition of draft for USP, Eplerenone, ASSAY) -

LC InertSearch Inertsil ODS-3
LC023 - Analysis of Lansoprazole (Under the Condition of the USP41-NF36, Lansoprazole Compounded Oral Suspension, ASSAY) -

LC InertSearch InertSustain C18
LC021 - Analysis of Cyanocobalamin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Cyanocobalamin_Method1) -

LC InertSearch Inertsil ODS-HL
LC016 - Analysis of Itraconazole (Under the Condition of USP-NF 2021 Issue 2, Itraconazole Capsules, ASSAY) -

LC InertSearch InertSustain C18
LC015 - Analysis of Itraconazole (Under the draft for USP, Itraconazole Oral Solution, ASSAY) -

LC InertSearch InertSustain C18
LC014 - Analysis of Itraconazole (Under the Condition of USP43-NF38, Itraconazole, ASSAY) -

LC InertSearch InertSustainSwift C18
LC012 - Analysis of Ethanol and Acetonitrile (Under the Condition for the Draft for USP, Tavaborole Topical Solution, Content of Alcohol) -

LC InertSearch Inertsil NH2
GA387 - Analysis of Ethanol and Acetonitrile (Under the Condition for the Draft for USP, Tavaborole Topical Solution, Content of Alcohol) -

GC InertSearch InertCap FFAP
LC009 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC InertSearch Inertsil ODS-3
LC008 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC InertSearch InertSustain C18
LC005 - Carbamazepine -

LC InertSearch InertSustainSwift C18
LC002 - Analysis of Phenazopyridine hydrochloride -

LC InertSearch InertSustain C18
LB998 - Analysis of Dextrose -

LC InertSearch InertSphere Sugar-2
LB997 - Analysis of Mesalamine -

LC InertSearch InertSustain C8
LB996 - Analysis of Mesalamine -

LC InertSearch InertSustain C8
LB995 - Analysis of Mesalamine -

LC InertSearch InertSustain C8
LB994 - Analysis of Mesalamine -

LC InertSearch InertSustain C8
LB993 - Analysis of Theophylline -

LC InertSearch InertSustainSwift C8
LB991 - Analysis of Progestrone and Methyltestrone -

LC InertSearch Inertsil WP300 C18
LB990 - Analysis of Xylazine -

LC InertSearch Inertsil WP300 C18
LB989 - Analysis of Xylazine -

LC InertSearch InertSustain C18
LB988 - Analysis of Xylazine -

LC InertSearch InertSustainSwift C8
LB987 - Analysis of Xylazine -

LC InertSearch Inertsil WP300 C18
LB986 - Analysis of Ganciclovir -

LC InertSearch Inertsil ODS-3
LB976 - Analysis of Dapagliflozin propandiol -

LC InertSearch InertSustain C18
LB975 - Analysis of Dapagliflozin propandiol -

LC InertSearch InertSustain C18
LB974 - Analysis of Dapagliflozin propandiol -

LC InertSearch InertSustain C18
LB965 - Analysis of Nicardipine Hydrochloride -

LC InertSearch InertSustain C8
LB961 - Analysis of Lidocaine -

LC InertSearch Insertsil WP300 C18
LB960 - Analysis of Lidocaine -

LC InertSearch Insertsil WP300 C18
LB958 - Analysis of Methyltestosterone and Progesterone -

LC InertSearch Insertsil WP300 C18
LB956 - Analysis of Sumatriptan succinate and Naproxen Sodium -

LC InertSearch Insertsil Ph-3
LB947 - Analysis of Glacial Acetic Acid -

LC InertSearch InertSustain AQ-C18
LB946 - Analysis of Glacial Acetic Acid -

LC InertSearch InertSustain AQ-C18
LB945 - Analysis of Glacial Acetic Acid -

LC InertSearch InertSustain AQ-C18
LB939 - Analysis of Potassium sucrose octasulfate -

LC InertSearch Inertsil NH2
LB938 - Analysis of Galantamine -

LC InertSearch InertSustain C18
GA368 - Analysis of Tetrahydrofuran and 1,4-butanediol -

GC InertSearch InertCap Pure-WAX
LB931 - Analysis of Acyclovir -

LC InertSearch Inertsil ODS-3
GA366 - Analysis of Ethylcellulose Dispersion Type B -

GC InertSearch InertCap Pure-WAX
GA365 - Analysis of Ethylcellulose Dispersion Type B -

GC InertSearch InertCap 624
GA364 - Analysis of Ethylcellulose Dispersion Type B -

GC InertSearch InertCap FFAP
GA363 - Analysis of Ethylcellulose Dispersion Type B -

GC InertSearch InertCap FFAP
LB925 - Analysis of Acyclovir -

LC InertSearch InertSustain Cyano
LB924 - Analysis of Acyclovir -

LC InertSearch InertSustain Cyano
LB919 - Analysis of Pitavastatin Calcium -

LC InertSearch InertCore Plus C18
LB914 - Analysis of Saxagliptin -

LC InertSearch InertSustain C18
LB913 - Analysis of Saxagliptin -

LC InertSearch InertSustain C18
LB912 - Analysis of Metformin Hydrochloride -

LC InertSearch Inertsil WP300 C18
LB911 - Analysis of Metformin Hydrochloride -

LC InertSearch Inertsil WP300 C18
LB902 - Analysis of Saxagliptin -

LC InertSearch InertSustain C18
LB901 - Analysis of Saxagliptin -

LC InertSearch InertSustain C18
LB900 - Analysis of Fesoterodine Fumarate -

LC InertSearch InertSustain C8
LB899 - Analysis of Fesoterodine Fumarate -

LC InertSearch InertSustainSwift C18
GA352 - Analysis of Dipropylene Glycol -

GC InertSearch InertCap WAX-HT
GA351 - Analysis of Dextran 40 -

GC InertSearch InertCap 1
LB896 - Analysis of Triptorelin Pamoate -

LC InertSearch InertSustain C18
LB895 - Analysis of Venlafaxine hydrochloride -

LC InertSearch InertSustainSwift C8
LB894 - Analysis of Ursodiol -

LC InertSearch Inertsil WP300
LB891 - Analysis of Saxagliptin -

LC InertSearch InertSustain C18 HP
LB890 - Analysis of Saxagliptin -

LC InertSearch InertSustain C18 HP
LB889 - Analysis of Propyl gallate -

LC InertSearch Inertsil WP300
LB888 - Analysis of Propyl gallate -

LC InertSearch Inertsil WP300
LB887 - Analysis of Propyl gallate -

LC InertSearch Inertsil ODS-4
LB885 - Analysis of Voriconazole -

LC InertSearch InertSustain C18
LB884 - Analysis of Voriconazole -

LC InertSearch InertSustain C18
LB883 - Analysis of Paclitaxel -

LC InertSearch InertSustain PFP
LB876 - Analysis of Cefoxitin -

LC InertSearch InertSustain C18
LB875 - Analysis of Levofloxacin -

LC InertSearch Inertsil ODS-3
LB859 - Analysis of Amoxicillin and Clavulanate potassium -

LC InertSearch Inertsil ODS-3
LB829 - Analysis of Sulfamethoxazole and Trimethoprim -

LC InertSearch Inertsil WP300 C18
LB828 - Analysis of Chloroprocaine Hydrochloride -

LC InertSearch InertSustain C18
LB751 - Analysis ofSulfamethoxazole and Trimethoprim -

LC InertSearch Inertsil WP300 C18
LB749 - Analysis of Ibuprofen（Under the Condeition of USP43-NF38) -

LC InertSearch Inertsil WP300 C18
LB745 - Analysis of of Metformin Hydrochloride Tablets（Under the Condeition of USP43-NF38, Glyburide and Metformin Hydrochloride Tablets) -

LC InertSearch InertSustain C18
LB740 - Analysis of Acetaminophen -

LC InertSearch Inertsil ODS-3
LB739 - Analysis of Acetaminophen -

LC InertSearch Inertsil ODS-3
LB696 - Analysis of Trifluoroacetic acid -

LC InertSearch InertSustain AQ-C18
LB695 - Analysis of acetic acid （USP） -

LC InertSearch InertSustainSwift C18
LB687 - Analysis of Ampicillin Hydrate -

LC InertSearch Inertsil ODS-4
LB681 - Analysis of Moxifloxacin -

LC InertSearch InertSustain Phenylhexyl
LB679 - Analysis of Cetylpyridinium chloride -

LC InertSearch InertSustain AX-C18
LB639 - Analysis of Levetiracetam (Under the Condition of USP42-NF37 1S, Levetiracetam Oral Solution) -

LC InertSearch InertSustainSwift C18
LB638 - Analysis of Levetiracetam (Under the Condition of USP42-NF37 1S, Levetiracetam Oral Solution) -

LC InertSearch InertSustain C18
LB637 - Analysis of Levetiracetam (Under the Condition of USP42-NF37 1S, Levetiracetam Extended-Release Tablets) -

LC InertSearch InertSustain C8
LB636 - Analysis of Levetiracetam (Under the Condition of USP42-NF37 1S, Levetiracetam Tablets) -

LC InertSearch InertSustainSwift C18
LB635 - Analysis of Levetiracetam (Under the Condition of draft for USP) -

LC InertSearch InertSustain AQ-C18 HP
LB634 - Analysis of Rivaroxaban (Under the Condition of draft for USP, Rivaroxaban Tablets) -

LC InertSearch InertSustainSwift C18
LB633 - Analysis of Rivaroxaban (Under the Condition of draft for USP) -

LC InertSearch InertSustainSwift C18
LB625 - Analysis of Prasugrel hydrochloride (Under the Condition of USP42-NF37) -

LC InertSearch InertSustainSwift C18
LB624 - Analysis of Etoposide phosphate (Under the Condition of draft for USP) -

LC InertSearch InertSustain Phenyl
LB623 - Analysis of Etoposide phosphate (Under the Condition of draft for USP) -

LC InertSearch InertSustain Phenyl
LB622 - Analysis of Venlafaxine hydrochloride (Under the Condition of USP41-NF36, Venlafaxine Hydrochloride Extended-Release Capsules) -

LC InertSearch InertSustain C18
LB621 - Analysis of Venlafaxine hydrochloride (Under the Condition of USP41-NF36, Venlafaxine Hydrochloride Extended-Release Capsules) -

LC InertSearch InertSustain C18
LB620 - Analysis of Venlafaxine hydrochloride (Under the Condition of USP41-NF36, Venlafaxine Tablets) -

LC InertSearch InertSustain C18
LB619 - Analysis of Venlafaxine hydrochloride (Under the Condition of USP41-NF36, Venlafaxine Hydrochloride) -

LC InertSearch InertSustain C8
LB618 - Analysis of Pregabalin (Under the Condition of USP41-NF36, Pregabalin) -

LC InertSearch Inertsil ODS-3
LB616 - Analysis of Levocetirizine (Under the Condition of USP41-NF36, Levocetirizine Dihydrochloride) -

LC InertSearch Inertsil SIL-100A
LB615 - Analysis of Cromolyn (Under the Condition of USP41-NF36, Cromolyn Sodium) -

LC InertSearch InertSustain C18
LT159 - Assay Test for Esomeprazole Magnesium Delayed -Release Capsules under USP Method -

LC Technical Note InertSustain C18
LT147 - D-Mannitol Analysis Under USP Method -

LC Technical Note InertSphere Sugar-2 HAMILTON HC-75（Ca2+）
LT131 - HPLC Columns Compliant with Pharmacopoeia (USP, EP and JP） -

LC Technical Note
LT099 - Analysis of Valsartan -

LC Technical Note InertSustain C18
LT098 - Analysis of Amlodipine -

LC Technical Note Inertsil ODS-4 HP
LT097 - Analysis of Pioglitazone Hydrocloride -

LC Technical Note Inertsil ODS-4 HP
LT096 - Analysis of Atorvastatin Calcium -

LC Technical Note Inertsil C8-4 Inertsil C8-4 HP
LB556 - Analysis of Mirtazapine -

LC InertSearch InertSustain C18
LB555 - Analysis of Mirtazapine (Under the Condition of draft for USP, Mirtazapine Compounded Oral Suspension, Veterinary) -

LC InertSearch Inertsil ODS-3
LB554 - Analysis of Mirtazapine (Under the Condition of USP41-NF36, Mirtazapine Orally Disintegrating Tablets) -

LC InertSearch InertSustainSwift C18
LB553 - Analysis of Mirtazapine (Under the Condition of USP41-NF36, Mirtazapine Tablets) -

LC InertSearch InertSustain C18
LB552 - Analysis of Mirtazapine (Under the Condition of USP41-NF36, Mirtazapine) -

LC InertSearch InertSustain C18
LB551 - Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe Tablets) -

LC InertSearch InertSustainSwift C18
LB550 - Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe Tablets) -

LC InertSearch InertSustainSwift C18
LB549 - Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe) -

LC InertSearch InertSustain PFP
LB548 - Analysis of Sitagliptin (Under the Condition of draft for USP, Sitagliptin and Metformin Hydrochloride Tablets) -

LC InertSearch InertSustain C18
LB547 - Analysis of Sitagliptin (Under the Condition of draft for USP, Sitagliptin and Metformin Hydrochloride Tablets) -

LC InertSearch InertSustain C18
LB546 - Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) -

LC InertSearch InertSustainSwift C18
LB545 - Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) -

LC InertSearch InertSustainSwift C18
LB536 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustain C18
LB535 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustainSwift C8
LB534 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustain C8
LB533 - Analysis of Dexamathasone Sodium Phosphate (Under the Condition of USP41-NF36, Dexamathasone Sodium Phosphate) -

LC InertSearch Inertsil ODS-3
LB512 - Analysis of Pioglitazone hydrochloride （Under the Condition of the draft for USP） -

LC InertSearch InertSustain C18
LB476 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LC InertSearch Inertsil Ph
LB475 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LC InertSearch Inertsil Ph-3
LB474 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LC InertSearch InertSustain Phenylhexyl
LB473 - Analysis of Solifenacin Succinate (Under the Condition of the draft for USP) -

LC InertSearch InertSustain Phenyl
LB463 - Analysis of Ibuprofen (Under the Condition of USP 39-NF34, Ibuprofen Oral Suspension) -

LC InertSearch InertSustain C8
LB462 - Analysis of Cephalexin (Under the Condition of USP 39-NF34) -

LC InertSearch InertSustain C18
LB461 - Analysis of Phenylephrine Hydrochloride (Under the Condition of USP 39-NF34, Phenylephrine Hydrochloride Injection) -

LC InertSearch InertSustain C18
LB460 - Analysis of Estradiol (Under the Condition of USP 39-NF34) -

LC InertSearch Inertsil ODS-3
LB459 - Analysis of Acetaminophen (Under the Condition of USP 39-NF34, Acetaminophen Capsules) -

LC InertSearch Inertsil ODS-3
LB458 - Analysis of Glyburide (Under the Condition of USP 39-NF34) -

LC InertSearch Inertsil C8
LB414 - Analysis of Esomeprazole magnesium (Under the Condition of USP 38-NF33, Esomeprazole magnesium Extended-release Tablets) -

LC InertSearch InertSustain C18
LB287 - Analysis of Sugar Spheres (Under the Condition of USP 37-NF32) -

LC InertSearch Inertsil NH2
LB200 - Analysis of Losartan potassium and Hydrochlorothiazide (Under the Condition of USP 35-NF30, Losartan potassium and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil C8-3
LA943 - Analysis of Azithromycin -

LC InertSearch InertSustain C18
LA939 - Analysis of Losartan Potassium (Inertsil ODS-4) -

LC InertSearch Inertsil ODS-4
LA938 - Analysis of Losartan Potassium (Inertsil ODS-4) -

LC InertSearch Inertsil ODS-4
LA937 - Analysis of Losartan Potassium (Inertsil ODS-3) -

LC InertSearch Inertsil ODS-3
LA936 - Analysis of Losartan Potassium (Inertsil ODS-3) -

LC InertSearch Inertsil ODS-3
LA922 - Analysis of Atorvastatin tablet -

LC InertSearch Inertsil C8-4
LA921 - Analysis of Atorvastatin -

LC InertSearch Inertsil C8-4
LA904 - Analysis of Bilberry extract (InertSustain C18) -

LC InertSearch InertSustain C18
LA898 - Analysis of Donepezil Hydrochloride-Impurities (Inertsil ODS-3) -

LC InertSearch Inertsil ODS-3
LA897 - Analysis of Donepezil Hydrochloride-Impurities (Inertsil ODS-4) -

LC InertSearch Inertsil ODS-4
GT107 - Simple Concentration Analysis of Lavender Flavor Components - Using MonoTrap RCC18 (solvent-extraction) -

GC Technical Note InertCap Pure-WAX
GT101 - Analysis of memantine hydrochloride in accordance with the USP -

GC Technical Note
GA291 - Memantine Hydrochloride(Under the Condition of United States Pharmacopeia 39, Organic Impurities) -

GC InertSearch InertCap 5
GA290 - Memantine Hydrochloride(Under the Condition of United States Pharmacopeia 39, Assay) -

GC InertSearch InertCap 5

Applications including "USP"

GA397 - Analysis of Nitromethane(Under the Condition of draft for USP, Tromethamine Hydrochloride, Limit of Nitromethane) -

LC110 - Analysis of Quinic acid, Malic acid, Citric acid, Shikimic acid (Under the Condition of draft for USP, Aronia melanocarpa Fruit Aqueous Dry Extract, IDENTIFICATION C.HPLC PROFILE AND RATIO OF ORGANIC ACIDS) -

LC109 - Analysis of Prazosin hydrochloride (Under the Condition of draft for USP, Prazosin Hydrochloride Compounded Oral Suspension, ASSAY) -

LC108 - Analysis of Formoterol fumarate (Under the Condition of draft for USP, Formoterol Fumarate Inhalation Solution, Assay) -

LC107 - Analysis of Terbinafine hydrochloride (Under the Condition of USP41-NF36,Terbinafine Tablets, IMPURITIES (LIMIT OF TERBINAFINE DIMER)) -

LC100 - Analysis of Omeprazole(Under the Condition of USP41-NF36, Omeprazole Delayed-Release Capsules, ASSAY) -

LL043 - Analysis of Azithromycin (Based on the Condition of USP-NF 2025 Issue 2 Mar, Azithromycin Tablets, ORGANIC IMPURITIES) -

LC099 - Analysis of Ascorbic acid (Under the Condition of draft for USP, Water-Soluble Vitamins Chewable Gels, Ascorbic acid, Method 1) -

LC098 - Analysis of Tramadol Hydrochloride (Under the Condition of draft for USP, Tramadol Hydrochloride Tablets, ASSAY) -

LC097 - Analysis of Azithromycin (Based on the Condition of USP NF 2025 Issue 2 Mar, Azithromycin Tablets, ORGANIC IMPURITIES) -

LC096 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ORGANIC IMPURITIES) -

LC095 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ASSAY) -

LC073 - Analysis of Yohimbine Hydrochloride(Under the Condition of USP41-NF36,Yohimbine Injection, ASSAY) -

LC072 - Analysis of Vitamin K１ (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PHYTONADIONE) -

LC071 - Analysis of Acetaminophen(Under the Condition of USP41-NF36, Acetaminophen Oral Solution, ASSAY) -

LC070 - Analysis of Vitamin A (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin A,Method 1) -

LC066 - Analysis of Cidofovir (Under the Condition of USP43-NF38, Cidofovir, ASSAY) -

LC065 - Analysis of Vitamin E (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 1) -

LC062 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin, DISSOLUTION) -

LC061 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin,ASSAY) -

LC058 - Analysis of Folic acid (Under the Condition of USP NF 2022 ISSUE 3, <411>FOLIC ACID ASSAY,_Procedure 1) -

LC057 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Tablets, ASSAY) -

LC056 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol, ASSAY) -

LC055 - Analysis of Dobutamine (Under the Condition of the USPNF 2023 Issue 2, Dobutamine Hydrochloride, ASSAY) -

LC054 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Injection, ASSAY) -

LC053 - Analysis of Folic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,FOLIC ACID_Method 2) -

LC052 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 2) -

LC051 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 1) -

LC050 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 3) -

LC049 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 2) -

LC044 - Analysis of Calcium Pantothenate (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Calcium Pantothenate, Method1) -

LC042 - Analysis of Nicotinic acid,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method3 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method3) -

LC041 - Analysis of Nicotinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method1 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method1) -

LC040 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, IMPURITIES, Limit of Free 4-Aminophenol) -

LC039 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, ASSAY) -

LC036 - Analysis of Zonisamide (Under the Condition of USP41-NF36, Zonisamide Compounded Oral Suspension, ASSAY) -

LC035 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide Capsules, ASSAY) -

LC034 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide, ASSAY) -

LC033 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Oil- and Water-Soluble Vitamins Minerals Tablets,BIOTIN_Method 3) -

LC032 - Analysis of D‐Biotin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,BIOTIN_Method 1) -

LC031 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Biotin) -

LC029 - Analysis of Riboflavin (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,RIBOFLAVIN_Method 2) -

LC028 - Analysis of Pyridoxine hydrochloride (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PYRIDOXINE HYDROCHLORIDE_Method 2) -

LC027 - Analysis of Nicotinamide (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,NIACINAMIDE_Method 2) -

LC026 - Analysis of Nicotinic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin_Method 2) -

LC025 - Analysis of Eplerenone (Under the Condition of draft for USP, Eplerenone Tablets, ASSAY) -

LC024 - Analysis of Eplerenone (Under the Condition of draft for USP, Eplerenone, ASSAY) -

LC023 - Analysis of Lansoprazole (Under the Condition of the USP41-NF36, Lansoprazole Compounded Oral Suspension, ASSAY) -

LC021 - Analysis of Cyanocobalamin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Cyanocobalamin_Method1) -

LC016 - Analysis of Itraconazole (Under the Condition of USP-NF 2021 Issue 2, Itraconazole Capsules, ASSAY) -

LC015 - Analysis of Itraconazole (Under the draft for USP, Itraconazole Oral Solution, ASSAY) -

LC014 - Analysis of Itraconazole (Under the Condition of USP43-NF38, Itraconazole, ASSAY) -

LC012 - Analysis of Ethanol and Acetonitrile (Under the Condition for the Draft for USP, Tavaborole Topical Solution, Content of Alcohol) -

GA387 - Analysis of Ethanol and Acetonitrile (Under the Condition for the Draft for USP, Tavaborole Topical Solution, Content of Alcohol) -

LC009 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC008 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC005 - Carbamazepine -

LC002 - Analysis of Phenazopyridine hydrochloride -

LB998 - Analysis of Dextrose -

LB997 - Analysis of Mesalamine -

LB996 - Analysis of Mesalamine -

LB995 - Analysis of Mesalamine -

LB994 - Analysis of Mesalamine -

LB993 - Analysis of Theophylline -

LB991 - Analysis of Progestrone and Methyltestrone -

LB990 - Analysis of Xylazine -

LB989 - Analysis of Xylazine -

LB988 - Analysis of Xylazine -

LB987 - Analysis of Xylazine -

LB986 - Analysis of Ganciclovir -

LB976 - Analysis of Dapagliflozin propandiol -

LB975 - Analysis of Dapagliflozin propandiol -

LB974 - Analysis of Dapagliflozin propandiol -

LB965 - Analysis of Nicardipine Hydrochloride -

LB961 - Analysis of Lidocaine -

LB960 - Analysis of Lidocaine -

LB958 - Analysis of Methyltestosterone and Progesterone -

LB956 - Analysis of Sumatriptan succinate and Naproxen Sodium -

LB947 - Analysis of Glacial Acetic Acid -